AI assistant
ASM International N.V. — Earnings Release 2019
Jul 24, 2019
3812_iss_2019-07-23_065e569d-905e-4022-879d-418d871d5826.pdf
Earnings Release
Open in viewerOpens in your device viewer

Almere, The Netherlands July 23, 2019, 6 p.m. CET
ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS
ASM International N.V. (Euronext Amsterdam: ASM) today reports its second quarter 2019 operating results (unaudited) in accordance with IFRS.
FINANCIAL HIGHLIGHTS
| Q2 2018 | Q1 2019 | Q2 2019 | |
|---|---|---|---|
| EUR million | |||
| New orders | 175.9 | 235.0 | 373.1 |
| Net sales | 208.7 | 248.8 | 363.3 |
| Gross profit margin % | 42.1% | 41.3% | 59.0% |
| Operating result | 38.3 | 47.0 | 150.2 |
| Result from investments (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013) |
21.6 | 3.1 | 2.0 |
| Amortization intangible assets (resulting from the sale of ASMPT stake in 2013) | (3.0) | (3.4) | (3.4) |
| Net earnings | 59.4 | 49.4 | 121.6 |
| Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares) |
62.4 | 52.8 | 125.0 |
- New orders were €373 million. Excluding €103 million related to the patent litigation settlement new orders were €270 million.
- Net sales for the second quarter 2019 were €363 million. Excluding €103 million related to the patent litigation settlement, net sales were €260 million and increased 5% compared to the previous quarter.
- Gross profit margin was 59.0% in Q2 2019 and 42.8% excluding the patent litigation settlement compared to 41.3% in the previous quarter.
- Operating result increased to €150 million. Excluding the patent litigation settlement operating result was stable at €47 million compared to the previous quarter.
- Normalized net earnings, including the patent litigation settlement, for the second quarter 2019 increased by €72 million compared to Q1 2019. Besides the positive impact of the patent litigation settlement net earnings in Q2 were negatively impacted by adverse currency effects and the increase in taxes due to the full utilization of the remaining net operating losses in the Netherlands. Results from investments decreased to €2 million.
COMMENT
Commenting on the results, Chuck del Prado, President and Chief Executive Officer of ASM International said: "In Q2 we realized sales of €363 million. Excluding the €103 million related to the reported patent litigation settlement, the sales of €260 million showed a 25% sales increase year-on-year, reaching the highest level ever, driven by continuous high demand in the logic/foundry segment. Our order intake, at €373 million (€270 million excluding the patent litigation settlement) was again very strong. Sales as well as order intake were above our guidance of respectively €230-250 million and €240-260 million. The high order intake in Q2 was led by logic. Our cash position in the quarter increased substantially and still excludes the cash proceeds from the litigation settlement which will come in in the next quarters. Based on this we today announced the authorization of a new €100 million share buyback program."
OUTLOOK
For Q3, on a currency comparable level, we expect sales of €250-270 million while bookings, on a currency comparable level, are expected to also be in the range of €250-270 million. For 2019, general expectations are now that the wafer fab equipment (WFE) market will decline with a high teens percentage. While expectations for the memory-segment have further weakened, the healthy demand in the logic and foundry segments in the first half is expected to continue in the second half of 2019. Based upon this current market view, we maintain our expectation to meaningfully outperform the WFE market in 2019.
SHARE BUYBACK PROGRAM
ASMI announced today that its Management Board authorized the repurchase of up to €100 million of the Company's common shares within the 2019-2020 time frame. This buyback program will be executed by intermediaries and will end as soon as the aggregate purchase price of the common shares acquired by ASMI has reached €100 million.
On May 20, 2019 the General Meeting of Shareholders authorized ASMI for a period of 18 months to acquire common shares up to 10% of its then issued capital.
The repurchase program is part of ASMI's commitment to use excess cash for the benefit of its shareholders.
ASMI further announces that the withdrawal of 5 million treasury shares has become effective as of July 23, 2019. As of that date, the number of issued shares is 51,297,394.
About ASM International
ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com.
Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forwardlooking statements to reflect future developments or circumstances.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
ASM International will host an investor conference call and web cast on Wednesday, July 24, 2019 at 15:00 Continental European Time (9:00 a.m. - US Eastern Time).
The teleconference dial-in numbers are as follows:
- United States: +1 631 510 7495
- International: +44 (0) 844 571 8892
- The Netherlands: +31 (0)20 714 3545
- Access Code: 1164706
A simultaneous audio webcast and replay will be accessible at www.asm.com.
CONTACT
Investor contact:
Victor Bareño
T: +31 88 100 8500
Media contact:
Ian Bickerton T: +31 625 018 512
ANNEX 1
OPERATING AND FINANCIAL REVIEW
Bookings
The following table shows the level of new orders for the second quarter of 2019 and the backlog at the end of the second quarter of 2019, compared to the previous quarter and the comparable quarter previous year:
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| Backlog at the beginning of the period | 217.9 | 301.5 | 292.0 | 171.2 | 301.5 |
| New orders for the period | 175.9 | 235.0 | 373.1 | 382.4 | 608.1 |
| Net sales for the period | (208.7) | (248.8) | (363.3) | (367.7) | (612.1) |
| FX-effect for the period | 4.0 | 4.3 | (2.1) | 3.2 | 2.1 |
| Backlog at the end of the period | 189.1 | 292.0 | 299.6 | 189.1 | 299.6 |
| Book-to-bill ratio (new orders divided by net sales) | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 |
The backlog increased from €292 million at the end of the first quarter 2019 to €300 million as per June 30, 2019. The bookings and the net sales in the quarter include €103 million related to the patent litigation settlement announced on July 1, 2019. The book-to-bill ratio for Q2 was 1.0. In terms of customer segments, new orders, excluding the patent litigation settlement, in the second quarter 2019 were led by logic, followed by memory and then foundry.
Net Sales
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| Equipment sales | 160.7 | 196.8 | 207.7 | 281.1 | 404.5 |
| Spares & service sales | 48.0 | 51.9 | 52.5 | 86.6 | 104.4 |
| Patent litigation settlement | — | — | 103.1 | — | 103.1 |
| Net sales | 208.7 | 248.8 | 363.3 | 367.7 | 612.1 |
Net sales for the second quarter 2019 increased by 46% compared to the previous quarter and increased by 74% year-on-year. Excluding the patent litigation settlement, net sales increased 5% compared to the previous quarter and increased 25% year-onyear. Net sales in the second quarter, excluding the patent litigation settlement, were led by logic followed by foundry and memory. The impact of currency changes was an increase of 1% quarter to quarter and an increase of 4% year-on-year.
Gross profit margin
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| Gross profit | 87.9 | 102.8 | 214.4 | 148.0 | 317.2 |
| Gross profit margin | 42.1% | 41.3% | 59.0% | 40.3% | 51.8% |
| Gross profit excluding patent litigation settlement | 87.9 | 102.8 | 111.3 | 148.0 | 214.1 |
| Gross profit margin excluding patent litigation settlement | 42.1% | 41.3% | 42.8% | 40.3% | 42.1% |
The gross profit margin increased from 41.3% in Q1 to 42.8% in Q2. For Q2 2018 gross profit margin was 42.1%. The gross profit margin in the quarter was 1.5% higher than in Q1 2019 mainly due to a better sales mix. The impact of currency changes on gross profit was an increase of 1% quarter to quarter and an increase of 2% year-on-year.
Selling, general and administrative expenses
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| SG&A expenses | 29.7 | 33.9 | 40.3 | 56.9 | 74.2 |
Selling, general and administrative (SG&A) expenses increased by 19% compared to the previous quarter. This increase was due to several reasons: legal costs related to patent disputes, the higher activity level, and investments to strengthen the ASMI processes and organization. As a percentage of sales (excluding the €103 million patent litigation settlement) SG&A expenses were 15% (Q1 2019: 14%, Q2 2018: 14%). The impact of currency changes on SG&A expenses was an increase of 1% quarter to quarter and an increase of 2% year-on-year.
Research and development expenses
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| Research and development expenses | 29.8 | 33.4 | 37.4 | 58.2 | 70.9 |
| Capitalization of development expenses | (12.7) | (15.3) | (17.1) | (22.8) | (32.4) |
| Amortization of capitalized development expenses | 2.8 | 3.0 | 3.4 | 5.6 | 6.4 |
| Impairment capitalized development expenses | — | 0.8 | — | — | 0.8 |
| R&D expenses | 19.9 | 21.9 | 23.8 | 40.9 | 45.7 |
Research and development (R&D) expenses increased by 9% compared to the previous quarter. As a percentage of sales (excluding the €103 million patent litigation settlement) R&D expenses remained stable at 9%. For the second quarter of 2018 this was 10%. The impact of currency changes on R&D expenses was an increase of 1% quarter to quarter and an increase of 4% year-on-year.
Operating result
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| Operating result | 38.3 | 47.0 | 150.2 | 50.0 | 197.2 |
| Operating result margin | 18.3% | 18.9% | 41.3% | 13.6% | 32.2% |
| Operating result excluding patent litigation settlement | 38.3 | 47.0 | 47.0 | 50.0 | 94.1 |
| Operating result margin excluding patent litigation settlement | 18.3% | 18.9% | 18.1% | 13.6% | 18.5% |
The operating profit margin decreased from 18.9% in Q1 to 18.1% in Q2. For Q2 2018 operating profit margin was 18.3%. The impact of currency changes on operating profit was an increase of 1% quarter to quarter and an increase of 2% year-on-year.
Financing costs
Financing costs are mainly related to translation results. The Q2 2019 results included a translation loss of €5 million compared to a gain of €4 million included in the Q1 2019 results and a gain of €8 million included in the Q2 2018 results. The translation results are mainly related to movements in the US dollar in the respective periods. A substantial part of ASMI's cash position is denominated in US dollar.
Result from investments
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| Result from investments (excluding amortization intangible assets resulting from the sale of the 12% stake of ASMPT) |
21.6 | 3.1 | 2.0 | 37.9 | 5.1 |
| Amortization intangible assets (resulting from the sale of the 12% stake of ASMPT) |
(3.0) | (3.4) | (3.4) | (6.8) | (6.8) |
| Result from investments | 18.6 | (0.3) | (1.4) | 31.1 | (1.7) |
Result from investments, which primarily reflects our approximate 25% shareholding in ASMPT, decreased to €2 million from €3 million in the previous quarter. ASMPT's net earnings, on a 100% basis, decreased with 35% to €8 million compared to the previous quarter. Q2 last year, also on a 100% basis, showed net earnings of €85 million. For further information on the Q2 results of ASMPT, please visit ASMPT's website www.asmpacific.com.
Amortization intangible assets resulting from the sale of the 12% stake of ASMPT in 2013 amounted to €3.4 million in Q2. For 2019, on a currency comparable basis, this amortization is expected to amount to €13.6 million.
Income tax
Income tax in the second quarter amounted to an expense of €22.6 million. Income tax in the previous quarter amounted to an expense of €1.6 million. The increase in tax expense is due to the complete utilization of the net operating losses in the Netherlands as a consequence of the patent litigation settlement.
Net earnings
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| Net earnings | 59.4 | 49.4 | 121.6 | 74.4 | 171.0 |
| Excluding: | |||||
| Amortization intangible assets (resulting from the sale of the | |||||
| 12% stake of ASMPT) | (3.0) | (3.4) | (3.4) | (6.8) | (6.8) |
| Normalized net earnings | 62.4 | 52.8 | 125.0 | 81.2 | 177.8 |
Normalized net earnings, including the patent litigation settlement, increased €72 million compared to Q1 2019.
Cash flow
| EUR million | Q2 2018 | Q1 2019 | Q2 2019 | YTD 2018 | YTD 2019 |
|---|---|---|---|---|---|
| Net cash from operating activities | (5.3) | 50.4 | 131.5 | 28.3 | 181.9 |
| Net cash from investing activities | (17.4) | (29.5) | (9.9) | (36.1) | (39.3) |
| Net cash from financing activities | (76.0) | (0.9) | (48.6) | (177.5) | (49.6) |
| Total net cash provided / (used) | (98.7) | 20.0 | 73.0 | (185.4) | 93.0 |
The patent litigation settlement had no cash effects in Q2 2019. The cash flow from operating activities was positively impacted by lower working capital needs. Cash used in investing activities during Q2 2019 was low as dividend from ASMPT was received. Cash used by financing activities in Q2 2019 was for dividend payments.
Balance sheet
| EUR million | December 31, 2018 | March 31, 2019 | June 30, 2019 |
|---|---|---|---|
| (audited) | |||
| Inventories | 171.8 | 174.0 | 170.4 |
| Accounts receivable | 173.5 | 193.4 | 260.4 |
| Other current assets | 45.0 | 37.6 | 46.4 |
| Accounts payable | (80.6) | (92.1) | (93.5) |
| Provision for warranty | (8.0) | (10.6) | (13.0) |
| Accrued expenses and other payables | (99.0) | (90.1) | (125.5) |
| Working capital | 202.7 | 212.2 | 245.3 |
Net working capital increased to €245 million compared to €212 million per March 31, 2019 (€203 million per December 31, 2018), mainly due to the outstanding receivable of the patent litigation settlement. The number of outstanding days of working capital, measured against quarterly sales, decreased to 61 days on June 30, 2019 from 77 days on March 31, 2019 (72 days on December 31, 2018).
Net working capital, excluding the patent litigation settlement, decreased to €144 million per June 30, 2019. Excluding this patent litigation amount, the number of outstanding days of working capital, measured against quarterly sales, decreased to 49 days on June 30, 2019.
Sources of liquidity
As per June 30, 2019, the Company's principal sources of liquidity consisted of €382 million in cash and cash equivalents and €150 million in undrawn bank lines.
CONSOLIDATED STATEMENTS OF PROFIT OR LOSS
| Three months ended June 30, | Six months ended June 30, | ||||
|---|---|---|---|---|---|
| 2018 | 2019 | 2018 | 2019 | ||
| EUR thousand, except per share data | (unaudited) | (unaudited) | (unaudited) | (unaudited) | |
| Net sales | 208,677 | 363,311 | 367,651 | 612,091 | |
| Cost of sales | (120,827) | (148,932) | (219,645) | (294,877) | |
| Gross profit | 87,850 | 214,379 | 148,006 | 317,214 | |
| Operating expenses: | |||||
| Selling, general and administrative | (29,685) | (40,321) | (56,905) | (74,223) | |
| Research and development | (19,913) | (23,817) | (40,911) | (45,718) | |
| Restructuring expenses | — | (80) | (149) | (80) | |
| Total operating expenses | (49,598) | (64,218) | (97,965) | (120,021) | |
| Operating result | 38,252 | 150,161 | 50,041 | 197,193 | |
| Net interest income (expense) | (379) | 11 | (881) | (6) | |
| Foreign currency exchange gains (losses) | 7,733 | (4,532) | 198 | (256) | |
| Result from investments | 18,600 | (1,433) | 31,071 | (1,683) | |
| Earnings before income taxes | 64,207 | 144,206 | 80,429 | 195,248 | |
| Income tax | (4,799) | (22,601) | (6,067) | (24,217) | |
| Net earnings | 59,408 | 121,605 | 74,362 | 171,031 | |
| Per share data: | |||||
| Basic net earnings | 1.09 | 2.46 | 1.36 | 3.46 | |
| Diluted net earnings (1) | 1.08 | 2.42 | 1.34 | 3.41 | |
| Weighted average number of shares used in | |||||
| computing per share amounts (in thousand): | |||||
| Basic | 54,318 | 49,530 | 54,554 | 49,430 | |
| Diluted (1) | 55,051 | 50,258 | 55,304 | 50,128 | |
| Outstanding shares: | 53,846 | 49,532 | 53,846 | 49,532 | |
| Treasury shares: | 8,452 | 6,765 | 8,452 | 6,765 |
(1) The calculation of diluted net earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in earnings of the Company. Only instruments that have a dilutive effect on net earnings are included in the calculation. The calculation is done for each reporting period individually. The possible increase of common shares caused by employee stock options and restricted shares for the three months ended June 30, 2019 is 728,119 common shares, and for the six months ended June 30, 2019 the possible increase is 697,889 common shares. Adjustments have been reflected in the diluted weighted average number of shares and net earnings per share for this period.
Amounts are rounded to the nearest thousand euro; therefore amounts may not equal (sub) totals due to rounding.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
| December 31, | June 30, | |
|---|---|---|
| 2018 | 2019 | |
| EUR thousand | (audited) | (unaudited) |
| Assets | ||
| Right-of-use assets | — | 29,607 |
| Property, plant and equipment | 148,749 | 148,884 |
| Goodwill | 11,270 | 11,270 |
| Other intangible assets | 149,927 | 174,783 |
| Investments in associates | 789,588 | 777,177 |
| Deferred tax assets | 11,316 | 4,359 |
| Other non-current assets | 11,865 | 10,522 |
| Evaluation tools at customers | 44,634 | 40,432 |
| Total non-current assets | 1,167,349 | 1,197,034 |
| Inventories | 171,826 | 170,386 |
| Accounts receivable | 173,450 | 260,437 |
| Income taxes receivable | 4,439 | 2,339 |
| Other current assets | 45,001 | 46,419 |
| Cash and cash equivalents | 285,907 | 381,535 |
| Total current assets | 680,623 | 861,116 |
| Total Assets | 1,847,972 | 2,058,150 |
| Equity and liabilities | ||
| Equity | 1,641,551 | 1,777,375 |
| Accrued expenses and other payables | — | 17,937 |
| Deferred tax liabilities | 12,170 | 12,220 |
| Total non-current liabilities | 12,170 | 30,157 |
| Accounts payable | 80,640 | 93,488 |
| Provision for warranty | 7,955 | 12,999 |
| Income taxes payable | 6,663 | 18,672 |
| Accrued expenses and other payables | 98,993 | 125,459 |
| Total current liabilities | 194,251 | 250,618 |
| Total Liabilities | 206,421 | 280,775 |
| Total Equity and Liabilities | 1,847,972 | 2,058,150 |
Amounts are rounded to the nearest thousand euro; therefore amounts may not equal (sub) totals due to rounding.
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2018 | 2019 | 2018 | 2019 | |
| EUR thousand | (unaudited) | (unaudited) | (unaudited) | (unaudited) |
| Cash flows from operating activities: | ||||
| Net earnings | 59,408 | 121,605 | 74,362 | 171,031 |
| Adjustments to reconcile net earnings to net cash from operating activities: |
||||
| Depreciation, amortization and impairments | 13,075 | 17,469 | 24,574 | 34,612 |
| Income tax | 4,799 | 22,601 | 6,067 | 24,217 |
| Result from investments | (18,600) | 1,433 | (31,071) | 1,683 |
| Other adjustments | (5,808) | 5,301 | 2,957 | 2,843 |
| Changes in other assets and liabilities: | ||||
| Accounts receivable | (60,023) | (67,389) | (5,128) | (84,636) |
| Inventories | (10,818) | 1,704 | (20,917) | 2,898 |
| Evaluation tools | (5,805) | 1,407 | (19,804) | (42) |
| Accounts payable | 11,856 | 2,308 | 18,964 | 12,163 |
| Other assets and liabilities | 7,119 | 26,371 | (17,316) | 20,299 |
| Income tax paid | (474) | (1,327) | (4,428) | (3,169) |
| Net cash from operating activities | (5,271) | 131,482 | 28,262 | 181,899 |
| Cash flows from investing activities: | ||||
| Capital expenditures | (19,003) | (9,223) | (27,303) | (21,742) |
| Capitalized development expenditure | (12,735) | (17,063) | (22,845) | (32,405) |
| Purchase of intangible assets | (262) | (93) | (532) | (1,681) |
| Dividend received from associates | 14,583 | 16,488 | 14,583 | 16,488 |
| Net cash from (used) in investing activities | (17,417) | (9,891) | (36,097) | (39,340) |
| Cash flows from financing activities: | ||||
| Purchase of treasury shares ASMI | (39,362) | — | (141,845) | — |
| Proceeds from issuance of treasury shares | 485 | 755 | 1,435 | 966 |
| Dividends to common shareholders ASMI | (37,108) | (49,390) | (37,108) | (49,390) |
| Capital repayment to common shareholders ASMI | — | — | — | (1,144) |
| Net cash used in financing activities | (75,984) | (48,636) | (177,517) | (49,569) |
| Exchange rate effects | 8,748 | (3,916) | 64 | 2,638 |
| Net increase (decrease) in cash and cash | (89,924) | 69,039 | (185,288) | 95,628 |
| equivalents Cash and cash equivalents at beginning of period |
741,096 | 312,496 | 836,461 | 285,907 |
| Cash and cash equivalents at end of period | 651,173 | 381,535 | 651,173 | 381,535 |
Amounts are rounded to the nearest thousand euro; therefore amounts may not equal (sub) totals due to rounding.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Basis of presentation
The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union.
Amounts are rounded to the nearest thousand euro; therefore amounts may not equal (sub) totals due to rounding.
Principles of consolidation
The Consolidated Financial Statements include the accounts of ASMI and its subsidiaries, where ASMI holds a controlling interest. All unrealized intercompany profits, transactions and balances have been eliminated in consolidation. Associates are investments in entities in which ASMI can exert significant influence but which ASMI does not control, generally by ASMI having between 20% and 50% of the voting rights. These entities are accounted for using the equity method.